Fewer people contracted HIV last year than at any point since the rise of the disease in the late 1980s, the United Nations ...
These daily oral antiretrovirals, more commonly referred to as PrEP (pre-exposure prophylaxis), such as Truvada®, are ...
Global HIV rates drop 20 but challenges persist in ending AIDS by 2030 Explore breakthroughs like lenacapavir prevention ...
Research shows many transgender women in the U.S. express interest in long-acting injectable PrEP but face barriers to ...
Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...
Dan O’Day drives Gilead's mission to end HIV worldwide, pioneering treatments like lenacapavir and championing global health ...
Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...
U.S. philanthropist and entrepreneur Bill Gates has opened up about the search for a lifetime HIV vaccine, rather than one ...